Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
IRVINE, Calif., July 31, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq:OCUL). Investors who purchased or otherwise acquired shares between May 5, 2017 and July 6, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the September 5, 2017 lead plaintiff motion deadline.
If you purchased Ocular shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, during the Class Period, Ocular made false and/or misleading statements and/or failed to disclose: that the Company’s management misled investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by Ocular contain bad product; that such manufacturing issues could endanger the approval of DEXTENZA by the Food and Drug Administration; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this news reached the public, shares of Ocular declined in value materially, which caused investors harm according to the Complaint.
If you want to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
